https://www.selleckchem.com/
Twelve patients (31%) experienced TIPS thrombosis. There were no significant long-term laboratory adverse events or deaths. At 36months, freedom from primary TIPS thrombosis was 63%; following secondary interventions, overall patency was increased to 81%. TIPS in chronic, noncirrhotic EHPVO with cavernomas and mesenteric venous thrombosis is technically feasible and does not adversely affect liver function. Most patients demonstrate subjective and objective benefit from TIPS. Improvement in patency rates are needed with proper timing of adjuvant anticoagula
Beğen
Yorum Yap
Paylaş
